NCT00262834View on ClinicalTrials.gov

Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

October 31, 2008

Study Completion Date

May 31, 2013

Conditions
Breast CancerStage I Breast CancerStage II Breast CancerStage III Breast Cancer
Interventions
DRUG

vorinostat

Given orally, conventional surgery to follow.

OTHER

conventional surgery

Undergo conventional surgery

Trial Locations (1)

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00262834 - Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast Cancer | Biotech Hunter | Biotech Hunter